Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,840 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于全资子公司产品获得美国FDA批准的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement about the FDA approval of a new drug specification by a wholly owned subsidiary. It contains no financial statements, earnings data, or details of board changes, dividends, or M&A transactions. It is a general regulatory/compliance announcement notifying investors of business developments. This matches the fallback category "Regulatory Filings (RNS)" for miscellaneous regulatory announcements.
2026-05-21 Chinese
关于控股股东一致行动人增持公司股份及后续增持计划的公告
Major Shareholding Notification Classification · 95% confidence The document is a stock exchange announcement by the company concerning its controlling shareholder’s concerted actor increasing its shareholding (detailing shares acquired, plan for further purchases, thresholds crossed, voting risks, etc.). This fits the Major Shareholding Notification category (MRQ).
2026-05-20 Chinese
招商证券股份有限公司关于普洛药业股份有限公司2026年股票期权激励计划首次授予相关事项之独立财务顾问报告
Regulatory Filings Classification · 82% confidence The document is an independent financial advisor’s fairness opinion report on the first grant of a 2026 stock option incentive plan. It does not contain quarterly or full-year financial statements (excluding IR/10-K), nor is it a meeting presentation, governance charter, earnings release or call transcript. It is a compliance/ regulatory disclosure required under Chinese stock incentive regulations. As no dedicated “fairness opinion” category exists, it falls under Regulatory Filings (RNS) as a general compliance document.
2026-05-18 Chinese
北京市康达律师事务所关于普洛药业股份有限公司2026年股票期权激励计划调整及首次授予相关事项的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (法律意见书) from Kangda Law Firm regarding a 2026 stock option incentive plan, providing legal analysis and compliance confirmation under PRC laws. It is not an AGM material, earnings release, financial report, proxy statement, share issuance announcement, or any of the other narrowly defined categories. It is essentially a compliance/legal opinion document submitted to regulators/investors, so it falls under the general “Regulatory Filings” catch-all category (RNS).
2026-05-18 Chinese
董事会薪酬与考核委员会关于2026年股票期权激励计划首次授予相关事项的核查意见
Remuneration Information Classification · 65% confidence The document is a formal opinion from the Board’s Remuneration and Appraisal Committee on the first grant under the company’s 2026 stock option incentive plan, including price adjustment due to dividend distribution and details of the initial grantees. It does not present financial statements or earnings but outlines executive/share-based remuneration policies and approvals, consistent with a Remuneration Information filing rather than an annual report, regulatory announcement of a report, or capital-raising notice.
2026-05-18 Chinese
北京市康达律师事务所关于普洛药业股份有限公司第二期员工持股计划受让价格调整的法律意见书
Regulatory Filings Classification · 98% confidence The document is a legal opinion (“法律意见书”) issued by Kangda Law Firm regarding the adjustment of the purchase price under an employee share ownership plan. It contains legal analysis, approvals, and attorney certification, but no financial statements or earnings figures. It is a certification/legal counsel document rather than a corporate financial report, dividend notice, or capital issuance announcement by the company itself. Under the classification rules, legal opinion letters and similar attestations default to Regulatory Filings (RNS).
2026-05-18 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.